{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Seo H"],"funding":["Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea","Soonchunhyang University Research Fund"],"pagination":["e3001648"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9154192"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(5)"],"pubmed_abstract":["The continued spread of drug-resistant tuberculosis is one of the most pressing and complex challenges facing tuberculosis management worldwide. Therefore, developing a new class of drugs is necessary and urgently needed to cope with the increasing threat of drug-resistant tuberculosis. This study aims to discover a potential new class of tuberculosis drug candidates different from existing tuberculosis drugs. By screening a library of compounds, methyl (S)-1-((3-alkoxy-6,7-dimethoxyphenanthren-9-yl)methyl)-5-oxopyrrolidine-2-carboxylate (PP) derivatives with antitubercular activity were discovered. MIC ranges for PP1S, PP2S, and PP3S against clinically isolated drug-resistant Mycobacterium tuberculosis strains were 0.78 to 3.13, 0.19 to 1.56, and 0.78 to 6.25 μg/ml, respectively. PPs demo"],"journal":["PLoS biology"],"pubmed_title":["A novel class of antimicrobial drugs selectively targets a Mycobacterium tuberculosis PE-PGRS protein."],"pmcid":["PMC9154192"],"funding_grant_id":["HI13C0828"],"pubmed_authors":["Kim S","Nam KW","Song HY","Yoon Y","Gil YS","Cho HD","Seo H","Islam MI","Lee BE","Choi J","Mahmud HA"],"additional_accession":[]},"is_claimable":false,"name":"A novel class of antimicrobial drugs selectively targets a Mycobacterium tuberculosis PE-PGRS protein.","description":"The continued spread of drug-resistant tuberculosis is one of the most pressing and complex challenges facing tuberculosis management worldwide. Therefore, developing a new class of drugs is necessary and urgently needed to cope with the increasing threat of drug-resistant tuberculosis. This study aims to discover a potential new class of tuberculosis drug candidates different from existing tuberculosis drugs. By screening a library of compounds, methyl (S)-1-((3-alkoxy-6,7-dimethoxyphenanthren-9-yl)methyl)-5-oxopyrrolidine-2-carboxylate (PP) derivatives with antitubercular activity were discovered. MIC ranges for PP1S, PP2S, and PP3S against clinically isolated drug-resistant Mycobacterium tuberculosis strains were 0.78 to 3.13, 0.19 to 1.56, and 0.78 to 6.25 μg/ml, respectively. PPs demo","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2025-04-22T11:51:54.117Z","creation":"2025-04-06T00:08:22.492Z"},"accession":"S-EPMC9154192","cross_references":{"pubmed":["35639773"],"doi":["10.1371/journal.pbio.3001648"]}}